Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access


Reduction of cholesterol and markers of oxidation in serum of hypercholestrolemic patients treated with lycosome formulation of simvastatin

Ivan M. Petyaev, Pavel Y. Dovgalevsky, Natalia E. Chalyk, Victor Klochkov, Nigel H. Kyle.

Background: Use of microencapsulated HMG-CoA reductase inhibitors (statins) might be extremely helpful in the prevention of their side effects.
Methods: 24 volunteers with hypercholesterolemia were given once daily 20 mg of lycosome-formulated Simvastatin fused with 7 mg lycopene (Lyco-Simvastatin) or the same amount of unmodified Simvastatin with no lycopene. Control patients received 7 mg of lycopene alone. Plasma lipids and oxidative markers were measured after 4 weeks of treatment.
Results: Both formulations of Simvastatin, but not lycopene, caused a reduction in serum total cholesterol and LDL at the intermediate (end of 2nd week) and final (end of 4th week) points of interventional period. Notably, reduction of total cholesterol and LDL in the 4th week of the trial was more profound in patients treated with Lyco-Simvastatin versus unmodified Simvastatin (P

Key words: Simvastatin, Lycopene, Hypercholesterolemia, Oxidative stress

Share this Article

Journal of Interdisciplinary Histopathology


ScopeMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons